[HTML][HTML] “Structure”-function relationships in eukaryotic transcription factors: the role of intrinsically disordered regions in gene regulation

JJ Ferrie, JP Karr, R Tjian, X Darzacq - Molecular Cell, 2022 - cell.com
Many principles of bacterial gene regulation have been foundational to understanding
mechanisms of eukaryotic transcription. However, stark structural and functional differences …

The p53 pathway: origins, inactivation in cancer, and emerging therapeutic approaches

AC Joerger, AR Fersht - Annual review of biochemistry, 2016 - annualreviews.org
Inactivation of the transcription factor p53, through either direct mutation or aberrations in
one of its many regulatory pathways, is a hallmark of virtually every tumor. In recent years …

MDM2/X inhibitors under clinical evaluation: perspectives for the management of hematological malignancies and pediatric cancer

V Tisato, R Voltan, A Gonelli, P Secchiero… - Journal of hematology & …, 2017 - Springer
The two murine double minute (MDM) family members MDM2 and MDMX are at the center
of an intense clinical assessment as molecular target for the management of cancer. Indeed …

PONDR-FIT: a meta-predictor of intrinsically disordered amino acids

B Xue, RL Dunbrack, RW Williams, AK Dunker… - … et Biophysica Acta (BBA …, 2010 - Elsevier
Protein intrinsic disorder is becoming increasingly recognized in proteomics research. While
lacking structure, many regions of disorder have been associated with biological function …

[HTML][HTML] The MDM2-p53 pathway revisited

S Nag, J Qin, KS Srivenugopal, M Wang… - Journal of biomedical …, 2013 - ncbi.nlm.nih.gov
The p53 tumor suppressor is a key transcription factor regulating cellular pathways such as
DNA repair, cell cycle, apoptosis, angiogenesis, and senescence. It acts as an important …

The roles of MDM2 and MDMX in cancer

O Karni-Schmidt, M Lokshin… - Annual Review of …, 2016 - annualreviews.org
For more than 25 years, MDM2 and its homolog MDMX (also known as MDM4) have been
shown to exert oncogenic activity. These two proteins are best understood as negative …

The tumor suppressor p53: from structures to drug discovery

AC Joerger, AR Fersht - Cold Spring Harbor …, 2010 - cshperspectives.cshlp.org
Even 30 years after its discovery, the tumor suppressor protein p53 is still somewhat of an
enigma. p53's intimate and multifaceted role in the cell cycle is mirrored in its equally …

Pathological unfoldomics of uncontrolled chaos: intrinsically disordered proteins and human diseases

VN Uversky, V Davé, LM Iakoucheva… - Chemical …, 2014 - ACS Publications
Pathological Unfoldomics of Uncontrolled Chaos: Intrinsically Disordered Proteins and Human
Diseases | Chemical Reviews ACS ACS Publications C&EN CAS Find my institution Log In …

Translating p53 into the clinic

CF Cheok, CS Verma, J Baselga… - Nature reviews Clinical …, 2011 - nature.com
Mutations in the TP53 gene are a feature of 50% of all reported cancer cases. In the other
50% of cases, the TP53 gene itself is not mutated but the p53 pathway is often partially …

Structural basis for high-affinity peptide inhibition of p53 interactions with MDM2 and MDMX

M Pazgier, M Liu, G Zou, W Yuan, C Li… - Proceedings of the …, 2009 - National Acad Sciences
The oncoproteins MDM2 and MDMX negatively regulate the activity and stability of the tumor
suppressor protein p53—a cellular process initiated by MDM2 and/or MDMX binding to the …